Novel Agonist Anti-GPCR Antibody to Trigger Resolution of Inflammation

• First-in-class antibody targeting GPCR with agonistic activity
• Anti-GPCR antibody to trigger resolution of inflammation and treat chronic inflammatory diseases
• Agonist Antibodies inhibit inflammatory immune cell recruitment and activation

Speakers:

Aurore Morello

Head of Research, Director of R&D Program

OSE Immunotherapeutics